Oncology drugs: market revenue Latin America 2016-2028

The revenue of the oncology drugs segment of the pharmaceuticals market in Latin America was forecast to continuously increase between 2024 and 2028 by in total 5.8 billion U.S. dollars (+69.54 percent). After the sixth consecutive increasing year, the indicator is estimated to reach 14.1 billion U.S. dollars and therefore a new peak in 2028.

Revenue of the oncology drugs market in Latin America from 2016 to 2028 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The oncology drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Citation formats